Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2019

Open Access 01-12-2019 | Back Pain | Research

Rehabilitation interventions in randomized controlled trials for low back pain: proof of statistical significance often is not relevant

Authors: Silvia Gianola, Greta Castellini, Davide Corbetta, Lorenzo Moja

Published in: Health and Quality of Life Outcomes | Issue 1/2019

Login to get access

Abstract

Background

An observed statistically significant difference between two interventions does not necessarily imply that this difference is clinically important for patients and clinicians. We aimed to assess if treatment effects of randomized controlled trials (RCTs) for low back pain (LBP) are statistically significant and clinically relevant, and if RCTs were powered to achieve clinically relevant differences on continuous outcomes.

Methods

We searched for all RCTs included in Cochrane Systematic Reviews focusing on the efficacy of rehabilitation interventions for LBP and published until April 2017. RCTs having sample size calculation and a planned minimal important difference were considered. In the primary analysis, we calculated the proportion of RCTs classified as “statistically significant and clinically relevant”, “statistically significant but not clinically relevant”, “not statistically significant but clinically relevant”, and “not statistically significant and not clinically relevant”. Then, we investigated how many times the mismatch between statistical significance and clinical relevance was due to inadequate power.

Results

From 20 eligible SRs including 101 RCTs, we identified 42 RCTs encompassing 81 intervention comparisons. Overall, 60% (25 RCTs) were statistically significant while only 36% (15 RCTs) were both statistically and clinically significant. Most trials (38%) did not discuss the clinical relevance of treatment effects when results did not reached statistical significance. Among trials with non-statistically significant findings, 60% did not reach the planned sample size, therefore being at risk to not detect an effect that is actually there (type II error).

Conclusion

Only a minority of positive RCT findings was both statistically significant and clinically relevant. Scarce diligence or frank omissions of important tactic elements of RCTs, such as clinical relevance, and power, decrease the reliability of study findings to current practice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hoffmann TC, Thomas ST, Shin PN, Glasziou PP. Cross-sectional analysis of the reporting of continuous outcome measures and clinical significance of results in randomized trials of non-pharmacological interventions. Trials. 2014;15:362.CrossRef Hoffmann TC, Thomas ST, Shin PN, Glasziou PP. Cross-sectional analysis of the reporting of continuous outcome measures and clinical significance of results in randomized trials of non-pharmacological interventions. Trials. 2014;15:362.CrossRef
2.
go back to reference Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976). 2000;25:3186–91.CrossRef Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976). 2000;25:3186–91.CrossRef
3.
go back to reference Abdul Latif L, Daud Amadera JE, Pimentel D, Pimentel T, Fregni F. Sample size calculation in physical medicine and rehabilitation: a systematic review of reporting, characteristics, and results in randomized controlled trials. Arch Phys Med Rehabil. 2011;92:306–15.CrossRef Abdul Latif L, Daud Amadera JE, Pimentel D, Pimentel T, Fregni F. Sample size calculation in physical medicine and rehabilitation: a systematic review of reporting, characteristics, and results in randomized controlled trials. Arch Phys Med Rehabil. 2011;92:306–15.CrossRef
4.
go back to reference Castellini G, Gianola S, Bonovas S, Moja L. Improving power and sample size calculation in rehabilitation trial reports: a methodological assessment. Arch Phys Med Rehabil. 2016;97:1195–201.CrossRef Castellini G, Gianola S, Bonovas S, Moja L. Improving power and sample size calculation in rehabilitation trial reports: a methodological assessment. Arch Phys Med Rehabil. 2016;97:1195–201.CrossRef
5.
go back to reference Fregni F, Imamura M, Chien HF, Lew HL, Boggio P, Kaptchuk TJ, Riberto M, Hsing WT, Battistella LR, Furlan A. International placebo symposium working g: challenges and recommendations for placebo controls in randomized trials in physical and rehabilitation medicine: a report of the international placebo symposium working group. Am J Phys Med Rehabil. 2010;89:160–72.CrossRef Fregni F, Imamura M, Chien HF, Lew HL, Boggio P, Kaptchuk TJ, Riberto M, Hsing WT, Battistella LR, Furlan A. International placebo symposium working g: challenges and recommendations for placebo controls in randomized trials in physical and rehabilitation medicine: a report of the international placebo symposium working group. Am J Phys Med Rehabil. 2010;89:160–72.CrossRef
6.
go back to reference Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med. 1978;299:690–4.CrossRef Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med. 1978;299:690–4.CrossRef
7.
go back to reference Wright JG. The minimal important difference: who's to say what is important? J Clin Epidemiol. 1996;49:1221–2.CrossRef Wright JG. The minimal important difference: who's to say what is important? J Clin Epidemiol. 1996;49:1221–2.CrossRef
8.
go back to reference van der Roer N, Ostelo RW, Bekkering GE, van Tulder MW, de Vet HC. Minimal clinically important change for pain intensity, functional status, and general health status in patients with nonspecific low back pain. Spine (Phila Pa 1976). 2006;31:578–82.CrossRef van der Roer N, Ostelo RW, Bekkering GE, van Tulder MW, de Vet HC. Minimal clinically important change for pain intensity, functional status, and general health status in patients with nonspecific low back pain. Spine (Phila Pa 1976). 2006;31:578–82.CrossRef
9.
go back to reference Gianola S, Andreano A, Castellini G, Moja L, Valsecchi MG. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain: the need to present minimal important differences units in meta-analyses. Health Qual Life Outcomes. 2018;16:91.CrossRef Gianola S, Andreano A, Castellini G, Moja L, Valsecchi MG. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain: the need to present minimal important differences units in meta-analyses. Health Qual Life Outcomes. 2018;16:91.CrossRef
10.
go back to reference Ostelo RW, Deyo RA, Stratford P, Waddell G, Croft P, Von Korff M, Bouter LM, de Vet HC. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine (Phila Pa 1976). 2008;33:90–4.CrossRef Ostelo RW, Deyo RA, Stratford P, Waddell G, Croft P, Von Korff M, Bouter LM, de Vet HC. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine (Phila Pa 1976). 2008;33:90–4.CrossRef
11.
go back to reference van Tulder M, Malmivaara A, Hayden J, Koes B. Statistical significance versus clinical importance: trials on exercise therapy for chronic low back pain as example. Spine (Phila Pa 1976). 2007;32:1785–90.CrossRef van Tulder M, Malmivaara A, Hayden J, Koes B. Statistical significance versus clinical importance: trials on exercise therapy for chronic low back pain as example. Spine (Phila Pa 1976). 2007;32:1785–90.CrossRef
12.
go back to reference Chan KB, Man-Son-Hing M, Molnar FJ, Laupacis A. How well is the clinical importance of study results reported? An assessment of randomized controlled trials. CMAJ. 2001;165:1197–202.PubMedPubMedCentral Chan KB, Man-Son-Hing M, Molnar FJ, Laupacis A. How well is the clinical importance of study results reported? An assessment of randomized controlled trials. CMAJ. 2001;165:1197–202.PubMedPubMedCentral
13.
go back to reference Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA. 1994;272:122–4.CrossRef Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA. 1994;272:122–4.CrossRef
14.
go back to reference Molnar FJ, Man-Son-Hing M, Fergusson D. Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. J Am Geriatr Soc. 2009;57:536–46.CrossRef Molnar FJ, Man-Son-Hing M, Fergusson D. Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. J Am Geriatr Soc. 2009;57:536–46.CrossRef
15.
go back to reference Pocock SJ, Geller NL, Tsiatis AA. The analysis of multiple endpoints in clinical trials. Biometrics. 1987;43:487–98.CrossRef Pocock SJ, Geller NL, Tsiatis AA. The analysis of multiple endpoints in clinical trials. Biometrics. 1987;43:487–98.CrossRef
16.
go back to reference Junger D. The rhetoric of research. Embrace scientific rhetoric for its power. BMJ. 1995;311:61.CrossRef Junger D. The rhetoric of research. Embrace scientific rhetoric for its power. BMJ. 1995;311:61.CrossRef
17.
go back to reference Chalmers I, Matthews R. What are the implications of optimism bias in clinical research? Lancet. 2006;367:449–50.CrossRef Chalmers I, Matthews R. What are the implications of optimism bias in clinical research? Lancet. 2006;367:449–50.CrossRef
18.
go back to reference Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252–60.CrossRef Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252–60.CrossRef
19.
go back to reference Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med. 2008;5 e217; discussion e217.CrossRef Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med. 2008;5 e217; discussion e217.CrossRef
20.
go back to reference Geha NN, Moseley AM, Elkins MR, Chiavegato LD, Shiwa SR, Costa LO. The quality and reporting of randomized trials in cardiothoracic physical therapy could be substantially improved. Respir Care. 2013;58:1899–906.CrossRef Geha NN, Moseley AM, Elkins MR, Chiavegato LD, Shiwa SR, Costa LO. The quality and reporting of randomized trials in cardiothoracic physical therapy could be substantially improved. Respir Care. 2013;58:1899–906.CrossRef
21.
go back to reference Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epidemiol. 2012;65:301–8.CrossRef Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epidemiol. 2012;65:301–8.CrossRef
22.
go back to reference Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309:814–22.CrossRef Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309:814–22.CrossRef
23.
go back to reference Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008;148:295–309.CrossRef Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008;148:295–309.CrossRef
24.
go back to reference Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ, Montori VM, Freyschuss B, Vist G, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. 2011;64:1283–93.CrossRef Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ, Montori VM, Freyschuss B, Vist G, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. 2011;64:1283–93.CrossRef
25.
go back to reference Crowe S, Fenton M, Hall M, Cowan K, Chalmers I. Patients', clinicians' and the research communities' priorities for treatment research: there is an important mismatch. Res Involv Engagem. 2015;1:2.CrossRef Crowe S, Fenton M, Hall M, Cowan K, Chalmers I. Patients', clinicians' and the research communities' priorities for treatment research: there is an important mismatch. Res Involv Engagem. 2015;1:2.CrossRef
26.
go back to reference Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71–2.CrossRef Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71–2.CrossRef
Metadata
Title
Rehabilitation interventions in randomized controlled trials for low back pain: proof of statistical significance often is not relevant
Authors
Silvia Gianola
Greta Castellini
Davide Corbetta
Lorenzo Moja
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2019
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-019-1196-8

Other articles of this Issue 1/2019

Health and Quality of Life Outcomes 1/2019 Go to the issue